Revolution Medicines presents preclinical data on RM-055 catalytic RAS(ON) inhibitor at AACR

Revolution Medicines

Revolution Medicines

RVMD

0.00
  • Revolution Medicines announced preclinical results for RM-055, an oral mutant-targeted catalytic RAS(ON) inhibitor, set for presentation April 21, 2026 at AACR Annual Meeting.
  • Studies showed deep, durable tumor regressions across multiple KRAS G12 mutant cancer models, supporting potential to extend durability of RAS-targeted therapy.
  • RM-055 also showed activity in tumors that had escaped prior RAS inhibitor treatment, positioning program as a potential option to counter acquired resistance.
  • Company highlighted mutant-selective pathway suppression in tumor models with reduced impact on normal tissue signaling, which could support combination use and dosing flexibility.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211730PRIMZONEFULLFEED9693589) on April 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.